← Back

Shattuck Labs Inc

Shattuck Labs, Inc. is a clinical-stage biotechnology company that develops antibodies for inflammatory and immune-mediated diseases in the United States. Its lead candidate, SL-325, is a death receptor 3 (DR3) blocking monoclonal antibody in Phase I trials for tumor necrosis factor-like ligand 1A. The company is also developing SL-425, a half-life extended version of SL-325, which is in IND-enabling chronic GLP toxicity studies, along with preclinical DR3-based bispecific antibodies for inflammatory bowel disease and other immune-mediated indications, and TRIM7, an oncology-focused program. Incorporated in 2016, Shattuck Labs is headquartered in Austin, Texas.

Price · split & dividend adjusted
News & notes moving STTK
STTK

Shattuck Labs reports Q2 GAAP EPS of -$0.12, in line with estimates

Shattuck Labs reported second-quarter 2026 GAAP earnings per share of -$0.12, matching consensus estimates. As of June 30, 2026, the company held approximately $208.3 million in cash, cash equivalents, and short-term investments, which it expects will fund operations into 2029.
STTK
Seeking Alpha·38dRead more →
© 2026 MarketDXAsset